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Abstract
Objective:  Review  the  risks  and  beneﬁts  of  postnatal  corticosteroid  use  for  the  treatment  of
bronchopulmonary  dysplasia,  considering  that  there  is  not  a  more  effective  therapy.
Data sources:  The  literature  review  was  carried  out  in  the  BIREME  database,  using  the  terms
‘‘bronchopulmonary  dysplasia  and  corticosteroid’’  in  the  LILACS,  IBECS,  MEDLINE,  Cochrane
Library, and  SciELO  databases,  selecting  the  most  relevant  articles  on  the  subject,  with  emphasis
on recent  literature  published  in  the  last  ﬁve  years.
Summary  of  the  data:  In  preterm  infants,  bronchopulmonary  dysplasia  is  still  a  common  prob-
lem and  remains  without  a  speciﬁc  therapy,  despite  knowledge  of  the  several  risk  factors.  The
treatment  essentially  consists  of  supportive  measures,  but  in  the  past,  corticosteroids  were
widely used,  as  they  are  the  only  medications  that  have  an  impact  on  disease  progression.
However, the  emergence  of  cerebral  palsy  associated  with  the  indiscriminate  use  of  cortico-
steroids has  prevented  the  prescription  of  this  drug  in  the  last  15  years.  Since  then,  no  new
measures  have  been  taken,  and  the  incidence  of  the  disease  tended  to  increase  during  this
period, creating  the  need  for  a  review  of  corticosteroid  use  and,  possibly,  more  restricted
indications.
Conclusions:  The  association  between  risks  and  beneﬁts  of  corticosteroid  use  in  preterm  infants
needs to  be  considered  due  to  the  fact  that  some  infant  subpopulations  may  show  more  beneﬁts
than risks,  such  as  those  using  mechanical  ventilation  with  difﬁcult  weaning.
© 2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved. Please cite this article as: de Oliveira Peixoto FA, Costa PS. Reviewing the use of corticosteroids in bronchopulmonary dysplasia. J Pediatr
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PALAVRAS-CHAVE
Displasia
broncopulmonar;
Corticoide;
Tratamento
Revendo  o  uso  dos  corticosteroides  em  displasia  broncopulmonar
Resumo
Objetivo:  O  objetivo  desse  estudo  é  revisar  os  riscos  e  benefícios  do  uso  do  corticoide  pós-natal
para o  tratamento  da  displasia  broncopulmonar,  uma  vez  que  ainda  não  há  outra  terapia  mais
eﬁcaz.
Fontes de  dados:  A  revisão  da  literatura  foi  realizada  pelo  banco  de  dados  da  BIREME,  utilizando
os termos  bronchopulmonary  dysplasia  and  corticosteroid  nos  sistemas  LILACS,  IBECS,  MEDLINE,
Biblioteca Cochrane,  SciELO,  sendo  selecionados  os  artigos  de  maior  relevância  sobre  o  tema,
com ênfase  na  literatura  dos  últimos  cinco  anos.
Síntese  dos  dados:  Em  recém-nascidos  prematuros,  a  broncodisplasia  ainda  é  um  problema  fre-
quente e  sem  terapêutica  especíﬁca,  apesar  do  conhecimento  dos  vários  fatores  de  risco.  O
tratamento,  basicamente,  é  feito  por  medidas  de  suporte,  mas  o  corticoide  no  passado  foi
largamente  utilizado  por  se  tratar  da  única  medicac¸ão  com  impacto  na  evoluc¸ão  da  doenc¸a.
Porém, o  aparecimento  de  paralisia  cerebral  associada  ao  uso  indiscriminado  do  corticoide
inviabilizou  a  prescric¸ão  da  droga  nos  últimos  15  anos.  Desde  então,  nenhuma  nova  medida  foi
tomada e  a  incidência  da  doenc¸a  tendeu  a  um  aumento  neste  período,  criando  a  necessidade
da revisão  do  uso  do  corticoide  e  de  possíveis  indicac¸ões  mais  restritas.
Conclusões:  A  relac¸ão  do  risco  e  benefício  dos  corticoides  utilizados  em  recém-nascidos  pre-
maturos precisa  ser  ponderada  diante  de  algumas  subpopulac¸ões  de  bebês  que  podem  ter  mais
benefícios que  riscos,  como  naqueles  em  ventilac¸ão  mecânica  e  com  desmame  difícil.
© 2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
a
d
o
S
i
o
g
R
S
h
t
s
p
l
b
f
r
d
u
d
s
s
p
o
i
The  lung  lesion  process  can  be  initiated  while  still  inIntroduction
Despite  perinatal  care  improvement  and  greater  survival
of  increasingly  young  infants,  bronchopulmonary  dyspla-
sia  (BPD)  is  still  a  common  complication  and  one  of  the
most  prevalent  and  important  sequelae  of  prematurity.
Between  2008  and  2013,  the  records  of  the  Rede  Brasileira
de  Pesquisas  Neonatais  (Brazilian  Network  of  Neonatal
Research)  showed  that,  despite  the  improved  survival  of
extremely  preterm  infants,  the  incidence  of  BPD  ranged
from  14.7%  to  14.0%,  remaining  virtually  unaltered.1
Better  prenatal  conditions,  early  surfactant  replace-
ment,  oxygen  supplementation,  mechanical  ventilation,
better  invasive  and  non-invasive  monitoring,  total  par-
enteral  nutrition,  and  extracorporeal  membrane  oxygen-
ation  are  examples  of  neonatology  advances  in  the  last  four
decades,  but  unfortunately  little  has  changed  regarding  BPD
prevention  or  treatment.2
BPD  predisposes  to  increased  hospital  length  of  stay  and
increases  neonatal  mortality.  During  childhood,  dysplastic
infants  have  worse  neurodevelopment  and  prolonged  hospi-
talizations,  in  addition  to  the  possibility  to  have  impaired
lung  function  throughout  life.3 Furthermore,  the  disease
represents  a  major  burden  on  the  family  structure  of  these
children,  in  addition  to  the  negative  impact  on  public  health
resources.
The  wait  for  new  therapeutic  measures  has  not  been
a  promising  one,  which  forces  researchers  to  try  to  bet-
ter  understand  the  risk  factors  and  preventive  measures
for  BPD.  Once  disease  onset  has  occurred,  the  treat-
ment  is  mostly  restricted  to  support  measures,  because
the  proposed  therapies  in  recent  years  have  not  altered
disease  evolution.  Among  these  therapies,  corticosteroid
u
r
ndministration  is  the  most  controversial;  its  use  started  to
ecrease  in  the  2000s,  when  it  was  believed  that  the  risks
f  using  corticosteroids  were  greater  than  their  beneﬁts.
ome  authors,  however,  attribute  this  decrease  to  the  rise
n  BPD  incidence.  Thus,  given  the  lack  of  new  therapeutic
ptions,  corticosteroids  are  causing  controversy  once  again,
enerating  new  insights  on  their  application.2,4
isk  factors
everal  risk  factors  are  involved  in  the  development  of  BPD;
owever,  it  is  difﬁcult  to  deﬁne  which  one  is  the  most  impor-
ant,  as  they  interact  in  different  ways  during  the  different
tages  of  preterm  newborn  development.  Moreover,  not  all
reterm  infants  develop  BPD,  as  individual  responses  to
ung  lesions  are  modulated  by  genetics,  epigenetics,  and
y  combining  different  disease  protection  and  resilience
actors.4
BPD  is  essentially  the  product  of  tissue  inﬂammatory
esponse  caused  by  its  own  repair.  As  the  lung  is  constantly
eveloping,  not  only  in  the  fetus,  but  also  in  the  newborn,
nderstanding  the  potential  lesions  that  can  occur  greatly
epends  on  the  maturation  phase  the  lesion.  From  alveolar
eptal  ﬁbrosis  found  in  classic  bronchopulmonary  dyspla-
ia,  observed  in  later  preterm  infants,  to  the  inhibition  of
ulmonary  alveolus  formation  found  in  ‘‘new  dysplasia,’’
bserved  in  preterm  infants  younger  than  32  weeks,  there
s  a  large  spectrum  of  the  same  disease.3--5tero;  the  best  known  factors  are:  intrauterine  growth
estriction,  lack  of  antenatal  corticosteroids,  chorioam-
ionitis,  and  gestational  hypertensive  disease.3,6,7
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Male  gender,  lower  gestational  age  at  birth,  as  well  as
arotrauma  and  excessive  oxygen  supplementation  in  the
elivery  room  are  early  risk  factors.7,8 Mechanical  ventila-
ion,  hyperoxia,  and  neonatal  infections  are  factors  that
rigger  an  inﬂammatory  process,  which  in  the  presence  of
n  immature  lung  represent  the  main  pillars  of  the  disease
hysiopathology.  In  a  review  article,  Bhandari4 mentions
hat  preterm  infants  with  lungs  at  the  canalicular/saccular
tage  of  development  are  more  likely  to  develop  BPD  and
hat  the  three  abovementioned  factors  (mechanical  ven-
ilation,  sepsis,  and  hyperoxia)  are  the  main  contributors
o  the  disease  pathogenesis.  The  author  also  suggests  that
t  is  more  important  to  avoid  neonatal  systemic  infections
han  mechanical  ventilation  in  lung  inﬂammatory  response
ecrease,  thus  having  a  greater  impact  on  the  reduction  of
PD  incidence.
Genetics  is  an  increasingly  studied  risk  factor  and  may
nterfere  in  many  different  ways,  interacting  with  exter-
al  aggressions  and  the  pulmonary  maturation  phase  of  the
reterm  infant.  Let  it  be  supposed,  for  instance,  that  a
peciﬁc  fetus  has  as  genetic  inheritance  a  particular  allele
f  the  gene  of  the  superoxide  dismutase  (SOD)  enzyme,
hich  promotes  susceptibility  of  the  terminal  bronchioles
o  oxygen  free  radicals.  However,  this  susceptibility  is  pro-
rammed  to  occur  from  24  to  28  weeks  of  gestation.  If  this
etus  is  born  at  32  weeks  of  gestational  age,  their  predis-
osition  to  BPD  will  be  lower,  not  only  due  to  increased
ung  maturity,  but  also  the  lower  inﬂuence  of  the  SOD  gene
t  that  particular  time  of  fetal  development.9 If,  on  one
and,  the  complexity  of  these  interactions  prevents  com-
lete  understanding  the  disease  physiopathology,  on  the
ther,  it  creates  the  hope  of  new  therapeutic  perspectives
or  the  future,  with  several  research  lines  to  be  developed.
For  now,  there  are  still  many  questions  and,  despite
he  better  understanding  of  BPD  pathogenesis,  few  answers
ave  been  provided  about  the  effectiveness  of  new
reatments.6,10
Primary  prevention  of  prematurity  is  still  the  best  method
o  prevent  BPD,  but  even  with  adequate  prenatal  care,  it  is
ot  always  possible  to  prevent  preterm  births  and  secondary
revention  is  then  discussed  as  an  attempt  to  prevent,  or  at
east  minimize,  the  damage  caused  by  the  disease.
revention
he  best  time  to  start  preventing  BPD  is  still  unclear,  as
t  is  not  known  when  disease  is  triggered  in  each  infant,
nd  it  may  even  be  triggered  during  the  fetal  stage.5 The
ncomplete  knowledge  of  the  disease’s  physiopathology,
ssociated  with  the  interactions  of  diverse  and  uncontrol-
able  risk  factors,  prevent  physicians  from  individualizing
he  appropriate  therapy  for  each  preterm  infant.  However,
ased  on  the  existing  knowledge  of  its  physiopathology,  fetal
hysiology,  and  the  impact  of  early  termination  of  a  preg-
ancy,  some  measures  have  been  studied  and  sometimes
pplied  in  clinical  practice.2,6,10
The  use  of  antenatal  corticosteroids  for  pulmonary  matu-
ation  decreases  neonatal  mortality,  respiratory  distress  syn-
rome  of  the  newborn  (RDS-NB),  and  peri-intraventricular
emorrhage.  Therefore,  it  is  a  formal  recommendation  for
regnant  women  in  preterm  labor.11 But  even  in  combination
d
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ith  postnatal  surfactant,  despite  the  abovementioned  ben-
ﬁts,  study  results  indicate  that  there  was  no  decrease  in  the
ncidence  of  BPD.6,10
The  association  of  barotrauma  or  volutrauma  with  BPD
ed  to  the  search  for  better  ways  to  ventilate  the  preterm
nfant,  with  gentler  ventilation  proposed,  with  the  use  of
ermissive  hypercapnia  and  guaranteed  volume  as  the  ven-
ilation  mode.  Despite  the  need  for  further  studies,  more
hysiological  ventilation,  with  volume  and  low  oxygen  con-
entrations,  without  leading  to  hypoventilation,  should  be
ecommended.8
The  caffeine  used  to  treat  apnea  of  prematurity  has  also
hown  to  decrease  the  risk  of  BPD,  although  the  action  mech-
nism  is  yet  to  be  clariﬁed.10 Körog˘lu et  al.12 evaluated
he  effect  of  caffeine  in  preterm  rats,  using  lipopolysaccha-
ide  as  proinﬂammatory  agent,  and  observed  that  there  was
n  improvement  in  lung  function,  suggesting  a  protective
ffect  through  an  anti-inﬂammatory  mechanism.  Moreover,
he  use  of  caffeine  has  been  shown  to  increase  the  response
f  carbon  dioxide  chemoreceptors,  improve  respiratory  mus-
le  performance,  and  increase  the  central  nervous  system
xcitability.6,10
Vitamin  A  has  several  cell  functions,  acting  as  a  potent
ntioxidant  agent.  In  addition  to  the  inability  to  metabolize
nd  eliminate  free  radicals,  preterm  infants  also  have  vita-
in  A  deﬁciency.6 When  the  vitamin  is  supplemented,  up  to
he  normalization  of  serum  levels,  it  is  possible  to  observe
he  decrease  in  oxygen  dependence  at  36  weeks  corrected
ge.  However,  in  the  long  term,  there  was  no  difference  in
he  ﬁnal  outcome  between  infants  who  received  high  doses
f  vitamin  A  and  those  who  did  not.13 Although  encouraging,
itamin  A  supplementation  is  also  hampered  by  the  limited
vailability  of  the  medication  outside  large  centers.
Oxidative  stress  of  injured  cells  releases  free  radicals.  As
ree  radicals  are  directly  involved  in  BPD  progression,  pro-
hylactic  supplementation  with  antioxidant  enzymes  may
e  promising.  Of  all  the  antiradical  treatments,  the  use  of
uperoxide  dismutase  appears  to  be  the  most  effective.7
avis14 studied  the  intra-tracheal  use  of  superoxide  dis-
utase  and  demonstrated  the  minimization  of  the  harmful
ffects  of  mechanical  ventilation  and  oxygen  use,  with  no
ssociated  toxic  effects.  McEvoy  et  al.3 mention  two  other
ntioxidants:  glutathione  precursors  and  cimetidine,  but  to
ate,  the  studies  have  shown  disappointing  outcomes.
Inhaled  nitric  oxide  improves  oxygenation  and  ventila-
ion  in  different  situations,  such  as  meconium  aspiration
yndrome,  sepsis,  and  pulmonary  hypertension,  as  well  as
howing  anti-inﬂammatory  properties.  According  to  these
ndings,  studies  have  been  carried  out  to  investigate  the
otential  beneﬁts  of  nitric  oxide  in  reducing  BPD  risk  or
everity.  However,  evidence  does  not  support  the  role  of
itric  oxide  in  preventing  the  disease,  although  it  is  not
et  clear  whether  there  is  any  speciﬁc  subgroup  of  preterm
nfants  that  could  beneﬁt  from  this  treatment.6
The  association  of  patent  ductus  arteriosus  (PDA)  with
PD  has  been  demonstrated  as  an  association  with  the  dis-
ase,  and  not  as  a  causative  factor.  Some  studies  have
hown  that  prophylactic  closure  of  the  ductus  arteriosus
oes  not  prevent  BPD,  whereas  some  suggest  that  the  treat-
ent  may  even  increase  the  risk  to  develop  the  disease.
he  use  of  indomethacin,  while  promoting  the  closure  of
he  ductus  arteriosus,  may  increase  the  incidence  of  BPD
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when  compared  to  spontaneous  closure.  Surgical  interven-
tion  also  showed  no  effect  in  preventing  BPD,  whereas
better  results  were  obtained  when  there  was  no  inter-
vention,  neither  pharmacological  nor  surgical  therapy.8
Nevertheless,  these  results  are  controversial  and  some-
times  discordant.  In  Brazil,  Sadeck  et  al.15 evaluated  494
preterm  infants  with  birth  weight  <1000  g  and  33  weeks
of  gestational  age,  and  concluded  that  both  pharmaco-
logical  and  surgical  treatments  decreased  the  mortality  in
very-low  birth  weight  preterm  infants.  However,  a  statisti-
cally  signiﬁcant  difference  was  demonstrated  regarding  BPD
incidence,  demonstrating  beneﬁts  in  the  conservative  and
pharmacological  treatment  groups  in  relation  to  the  surgi-
cal  treatment  group,  reinforcing  the  need  to  perform  more
randomized  controlled  trials  to  understand  PDA  in  preterm
infants.
Neonatal  sepsis  has  a  close  association  with  BPD  and  is
considered  an  independent  risk  factor,  as  well  as  mechan-
ical  ventilation  and  oxygenation.  Lahra  et  al.16 reported
an  increase  in  BPD  in  a  cohort  of  798  preterm  infants
with  gestational  age  <30  weeks  when,  in  the  presence  of
chorioamnionitis,  the  infant  showed  associated  neonatal
sepsis.  Differently  from  this  result,  preterm  infants  who  did
not  develop  neonatal  sepsis,  even  when  undergoing  treat-
ment  for  chorioamnionitis,  had  a  lower  incidence  of  BPD.
Although  the  direct  role  of  infection  in  the  development  of
BPD  is  not  completely  understood,  the  evidence  suggests
that  systemic  inﬂammation,  associated  with  vascular  per-
meability  alterations,  is  a  major  cause  of  cell  injury  and  the
consequent  alveolarization  process  interruption.5,7 Some
animal  studies  suggest  that  preventing  neonatal  infection,
localized  or  systemic  (sepsis),  is  even  more  important  in
reducing  the  inﬂammatory  response  of  the  lungs  than  inva-
sive  mechanical  ventilation.  In  other  words,  it  is  speculated
that  there  might  be  an  even  greater  impact  in  reducing  BPD
rates  through  neonatal  infection  control,  even  in  patients
undergoing  invasive  mechanical  ventilation.4
Although  some  therapies  may  be  suggested  based  on  the
knowledge  of  BPD  predictors,  it  has  not  been  sufﬁcient  to
change  the  disease  incidence  over  the  years.  Given  this  sce-
nario,  still  an  unclear  one,  corticosteroids  are  once  again
being  discussed.
Once  again,  the  corticosteroid
Historically,  the  treatment  of  BPD  has  always  been  the
main  indication  for  corticosteroid  use  in  neonatology,  even
though  other  indications,  such  as  refractory  shock  and  post-
extubation  laryngitis,  are  becoming  frequent.
Since  it  was  established  that  inﬂammation  is  a
determinant  for  BPD,  corticosteroids,  for  their  potent
anti-inﬂammatory  action,  have  been  widely  studied  as  a
therapeutic  or  prophylactic  tool.  The  systemic  use  of  corti-
costeroids  not  only  reduces  inﬂammation  but  also  increases
surfactant  production,  accelerates  lung  cell  differentia-
tion,  reduces  vascular  permeability,  and  increases  lung  ﬂuid
resorption.  These  actions  result  in  increased  lung  compli-
ance  and  tidal  volume,  improving  ventilatory  function.6,8
Regardless  of  the  mechanism,  corticosteroids  have  posi-
tive  results  in  the  treatment  of  preterm  infants  with  BPD.
The  knowledge  of  these  effects  led  to  its  abusive  use,
s
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specially  in  the  late  1990s,  when  there  was  a  tendency  for
ts  increasingly  early  use,  even  in  less  severe  cases.17
The  postnatal  effectiveness  of  dexamethasone  in  the
reatment  of  mechanical  ventilation-dependent  BPD  was
rst  demonstrated  in  1983  by  Mammel  et  al.18 Over  time
nd  due  to  the  promising  results,  the  use  of  postnatal  high-
ose  corticosteroids  for  extended  periods  of  time  became
outine,  particularly  in  extremely  preterm  infants,  to  the
oint  of  having  a  formal  indication  for  BPD  prevention.  In
anada,  between  January  1996  and  October  1997,  25%  of
ery-low  birthweight  infants  started  receiving  systemic  cor-
icosteroids  in  the  ﬁrst  week  of  life.  In  the  United  States,
his  rate  was  19%  between  1995  and  1996.19
If  in  the  short  term,  the  early  use  of  corticosteroids
emonstrated  decreased  dependence  on  mechanical  ven-
ilation  and  oxygen  as  immediate  beneﬁts,  in  addition  to
he  reduced  incidence  of  BPD,  it  would  be  expected  that,
n  the  long  term,  there  would  also  be  a  reduction  in  neuro-
ogical  sequelae  associated  with  BPD.  However,  after  more
han  a  decade  of  widespread  use  of  postnatal  systemic  cor-
icosteroids,  differently  from  what  was  expected,  clinical
rials  started  to  demonstrate  a signiﬁcant  increase  in  the
ncidence  of  cerebral  palsy.18
Gradually,  the  adverse  effects  of  treatment  with
orticosteroids  were  established:  hyperglycemia,  sys-
emic  hypertension,  hypertrophic  cardiomyopathy,  diges-
ive  bleeding,  gastrointestinal  perforation,  hypothalamic--
ituitary--adrenal  axis  suppression,  failure  to  thrive,
ecelerating  head  circumference  growth  rate,  neurodevel-
pmental  delays,  and  lung  structure  alterations.2
In  2010,  Halliday  et  al.  analyzed  28  clinical  trials
hat  compared  the  early  use  of  postnatal  systemic  cor-
icosteroids  in  3740  participants.  They  found  that  the
roup  receiving  dexamethasone  showed  earlier  extubation,
ecreased  mortality,  and  reduced  incidence  of  pulmonary
isease,  when  evaluated  at  both  28  days  of  life  and
t  36  weeks  corrected  age.  There  was  no  difference
etween  treatment  and  control  groups  regarding  neonatal
nfection,  severe  peri-intraventricular  hemorrhage,  peri-
ntraventricular  leukomalacia,  necrotizing  enterocolitis,
nd  pulmonary  hemorrhage.  However,  there  was  a  pro-
ibitive  increase  of  cerebral  palsy  cases  in  the  treatment
roup  (RR:  1.45,  95%  CI:  1.06--1.98).20 Nevertheless,  it  is
oteworthy  that  these  reported  adverse  effects  are  based
n  studies  with  high-dose  dexamethasone  administered  in
he  ﬁrst  days  of  life  and  maintained  for  extended  periods.
After  2002,  the  use  of  corticosteroids  was  formally  dis-
ouraged  by  the  American  Academy  of  Pediatrics  and  the
anadian  Pediatric  Society  (Committee  on  Fetus  and  New-
orn,  2002),  although  some  authors  have  pondered  that
 prudent  assessment  of  the  available  data  should  have
een  conducted  before  the  formal  drug  contraindication.21
onetheless,  what  happened  was  exactly  the  opposite,  and
here  was  a  sudden  interruption  of  all  studies  related  to
he  use  of  postnatal  corticosteroids.  The  fact  is  that,  at
hat  time,  no  distinction  was  made  between  treatments
ith  early  and  indiscriminate  use  of  corticosteroids  and  their
ater  use,  with  more  speciﬁc  indications.17In  2003,  Halliday  et  al.  began  studying  the  use  of  cortico-
teroids  in  relation  to  the  time  of  therapy  onset,  classifying
he  treatment  in  three  different  subgroups:  early,  for  the
se  within  the  ﬁrst  96  h  of  life;  moderately  early,  for  the
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se  between  seven  and  14  days  of  life  and;  late,  for  the  use
fter  two  weeks  of  life.22,23 The  authors  conﬁrmed  that  early
dministration  of  corticosteroids,  despite  the  immediate
mprovement  in  patient’s  ventilation,  should  be  proscribed
ecause  of  its  association  with  the  high  risk  of  cerebral  palsy.
Moderately  early  administration  was  evaluated  in  seven
andomized  clinical  trials  with  a  sample  of  669  patients,
howing  better  ventilatory  weaning  and  decreased  BPD
ncidence,  similar  to  that  found  with  early  corticosteroid
dministration.  They  also  reported  that  adverse  effects,
uch  as  hypertension,  hyperglycemia,  gastrointestinal  hem-
rrhage,  hypertrophic  cardiomyopathy,  neonatal  infection,
nd  mainly,  neurodevelopmental  alterations,  were  not
bserved.22
The  meta-analysis  of  dexamethasone  use  after  the  third
eek  of  life  consisted  of  nine  randomized  clinical  trials,
esulting  in  a  total  of  562  studied  patients.  The  group  that
sed  corticosteroids  had  lower  rates  of  extubation  failure
nd  BPD  incidence.  The  observed  short-term  adverse  events
ere:  increase  in  blood  pressure,  urinary  glucose  levels,  and
light  increase  in  retinopathy  of  prematurity  severity,  but
o  increase  in  cases  of  blindness.  There  was  no  difference
etween  the  groups  regarding  infection,  enterocolitis,  and
astrointestinal  bleeding.  In  the  group  that  used  corticoste-
oids,  no  neurodevelopmental  delay  was  observed,  although
here  are  limitations  in  the  used  methodology  for  the  long-
erm  assessment  of  these  children  in  some  of  these  clinical
rials.23
Although  none  of  the  studies  with  dexamethasone  use
fter  seven  days  of  life  showed  an  increased  risk  of  cerebral
alsy,  the  authors  recommend  caution  in  the  indication  of
orticosteroids,  reserving  them  for  cases  with  greater  difﬁ-
ulty  in  mechanical  ventilation  weaning,  also  recommending
maller  doses  and  the  shortest  possible  time  of  use.20,22,23
The  problem  in  creating  a  guideline  for  clinical  practice
ased  on  interpretations  of  these  randomized  clinical  trials
s  that  there  may  be  overlapping  of  two  confounding  factors.
he  ﬁrst  factor  is  that  the  effects  of  corticosteroids,  both
eneﬁcial  and  adverse,  as  well  as  with  any  other  drug,  are
ensitive  to  the  dose  and  treatment  duration.  The  second
actor  is  related  to  prematurity,  as  the  fetus  or  newborn  are
t  different  developmental  stages,  which  probably  results  in
ifferent  susceptibility  to  the  effects  of  corticosteroids.  For
nstance,  given  the  knowledge  that  preterm  infants  are  more
nstable  in  the  ﬁrst  days  of  life  and  knowing  that  severe
vents,  such  as  peri-intraventricular  hemorrhage,  are  more
ikely  to  occur  in  the  ﬁrst  week  of  life,  it  is  possible  that
he  adverse  effects  of  corticosteroids  may  be  exacerbated
y  the  infant’s  postnatal  age.  These  two  factors  may  also  be
otentiated  by  other  risk  factors  for  BPD.  In  this  scenario,
he  return  of  corticosteroids  opens  new  discussions.17
As  the  indiscriminate  use  of  corticosteroids  in  the  1990s
ncreased  the  cases  of  cerebral  palsy,  their  sudden  disuse
n  the  2000s  reﬂected  in  the  increasing  incidence  of  BPD,
specially  in  very-low  weight  preterm  infants.19
Both  prematurity  and  BPD,  as  well  the  corticosteroid  use,
re  associated  with  worsened  neurological  development,
nd  it  is  likely  that  the  negative  results  of  early  steroid  use
o  prevent  BPD  may  vary  according  to  disease  incidence  in
he  control  group.24,25 That  is,  the  negative  impact  of  early
se  of  corticosteroids  is  inversely  proportional  to  BPD  inci-
ence.  A  group  with  low  incidence  of  BPD  would  show  more
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arm  than  good  as  a  result  of  early  corticosteroid  use.  How-
ver,  if  the  incidence  of  BPD  is  high  in  this  population,  there
ill  be  a  higher  incidence  of  survivors  without  neurologi-
al  impairment.  Considering  this  hypothesis,  in  2006  Doyle
t  al.25 re-evaluated  the  effect  of  early  use  of  steroids  in
reterm  infants,  based  on  20  randomized  controlled  trials.
he  authors  also  assessed  the  effects  of  corticosteroids  in
he  long  term  (at  least  up  to  12  months  of  chronological
ge)  in  14  of  the  20  selected  clinical  trials.  Through  anal-
sis  by  meta-regression,  the  authors  correlated  the  results
f  clinical  trials  with  some  of  the  most  important  risk  fac-
ors  for  the  development  of  BPD  and  found  an  alternative
xplanation  for  the  adverse  effects  of  early  treatment  of
orticosteroids  in  preterm  infants.  The  explanation  is  that
orticosteroids  do  not  have  only  direct  harmful  effects,  but
lso,  by  promptly  improving  pulmonary  function,  indirectly
mprove  brain  development.  Thus,  future  studies  must  ﬁnd
he  line  of  demarcation,  below  which  the  risks  of  treatment
ith  corticosteroids  would  overlap  the  risks  of  the  disease.17
n  2014,  the  authors  extended  the  meta-analysis  with  the
atest  six  new  clinical  trials  and  suggested  the  use  of  risk
redictors  to  guide  the  decision  of  using  corticosteroids  in
he  treatment  of  BPD  in  mechanical-ventilation  dependent
reterm  infants.25
During  the  preterm  infant’s  follow-up,  several  triggers
f  the  systemic  inﬂammatory  response  can  interact  with
ach  other,  even  with  one  or  more  of  these  factors,
otentiating  the  injuries.  Neonatal  sepsis  associated  with
horioamnionitis  occurs  simultaneously  with  the  early  use
f  corticosteroids,  and  both  interact  with  bronchopulmonary
ysplasia,  making  it  difﬁcult  to  recognize  the  contribution
f  each  factor  in  the  development  of  cerebral  palsy.  Hent-
es  et  al.26 evaluated  94  preterm  infants  with  very-low  birth
eight  and  neonatal  sepsis  and  were  able  to  associate  the
nfection  with  an  increased  ventilatory  support  time,  longer
ospital  stays,  and  higher  incidence  of  bronchopulmonary
ysplasia  and  seizures.
Another  consideration  is  that  most  of  the  early  stud-
es  were  with  patients  using  high-dose  dexamethasone  with
arly  treatment  onset  and  prolonged  duration.  Some  of
hese  patients  started  corticosteroids  before  72  h  of  life,
ore  as  prevention  than  treatment  of  BPD,  and  continued
ts  use  for  up  to  42  days  of  life.17
Titration  of  the  ideal  dose  for  the  use  of  corticosteroids
s  also  subject  to  debate.  The  ﬁrst  clinical  trials  used  a
tandard  dose  of  0.5  mg/kg  of  dexamethasone,  which  was
educed  slowly  over  several  weeks.  The  most  recent  clinical
rial  used  lower  initial  doses  of  0.2,  0.15,  or  0.1  mg/kg,  in
ecreasing  doses,  during  seven  to  10  days;  the  treatment
as  terminated  if  there  was  no  therapeutic  response.16
In  recent  years,  the  role  of  other  corticosteroids,  rather
han  dexamethasone,  has  been  questioned  regarding  their
se  in  BPD  prophylaxis  or  treatment.  Because  hydrocor-
isone  is  a natural  hormone,  its  higher  degree  of  safety
as  postulated  when  compared  to  dexamethasone.  Watter-
erg  et  al.27 evaluated  the  use  of  hydrocortisone  for  the
rophylaxis  of  early  adrenal  insufﬁciency,  aiming  at  BPD
revention.  The  study  was  carried  out  in  preterm  infants
eighing  <1000  g  with  mechanical  ventilation,  randomized
nto  two  groups,  with  and  without  hydrocortisone.  The  study
ad  to  be  terminated  due  to  the  increase  in  cases  of  intesti-
al  perforations.  However,  in  cases  that  had  already  been
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concluded,  there  were  no  signiﬁcant  differences  for  mortal-
ity  and  BPD,  except  in  those  exposed  to  chorioamnionitis,
which  showed  lower  mortality  and  lower  incidence  of  BPD
when  treated  with  hydrocortisone.
Finally,  the  search  for  steroids  with  the  same  therapeutic
effect  and  fewer  adverse  effects  than  dexamethasone  con-
tinues.  The  inhaled  route,  for  instance,  seemed  promising
due  to  two  advantages:  direct  drug  action  on  the  inﬂam-
mation  site  and  rapid  action  onset,  with  low  doses  and
less  systemic  absorption.  However,  there  is  very  little  evi-
dence  of  the  efﬁcacy  of  inhaled  corticosteroids  to  justify
their  routine  use.28 A  clinical  trial  started  in  2009  and  still
in  progress,  proposes  the  study  of  850  infants  between  23
and  27  weeks  corrected  age,  randomized  within  12  h  of  life
into  two  groups:  inhaled  budesonide  vs.  placebo.  This  study,
known  as  NEUROSIS  (Neonatal  European  Study  of  Inhaled
Steroids),  will  evaluate  survivors  without  BPD  as  the  pri-
mary  outcome,  when  they  reach  36  weeks  corrected  age.
Subsequently,  the  study  participants  will  be  followed  for
the  neurological  outcome  up  to  18--22  weeks  corrected  age.
Additional  pharmacodynamics  studies  and  a  study  excerpt
to  assess  genetic  susceptibility  will  also  be  performed  in  the
future.29
In  2008,  Yeh  et  al.30 published  a  pilot  study  on  the
use  of  budesonide  instilled  directly  into  the  trachea  and
distributed  to  the  lung  periphery  through  the  surfactant.
Preliminary  results  showed  no  signiﬁcant  difference  in  the
incidence  of  BPD  or  mortality  when  assessed  alone.  However,
after  combining  the  two  outcomes,  death  and  BPD,  the  best
results  were  observed  in  the  treatment  group.  Currently,  Yeh
et  al.  are  replicating  the  same  study  at  multicenter  level.
Conclusion
Given  the  abovementioned  facts,  it  is  now  time  to  discuss
preterm  subpopulations  with  clear  indications  for  the  use
of  corticosteroids  in  the  treatment  of  BPD.  Preterm  infants,
on  mechanical  ventilation  and  showing  difﬁculty  in  weaning,
are  probably  the  starting  point  for  further  research.
In  the  neonatal  intensive  care  unit  at  Hospital  das  Clini-
cas,  Universidade  Federal  de  Goiás,  systemic  corticosteroids
are  used  in  selected  cases.  The  criteria  are:  preterm  infants
on  mechanical  ventilation  for  more  than  two  weeks,  show-
ing  difﬁculty  in  weaning  from  mechanical  ventilation,  after
excluding  other  causes,  such  as  sepsis,  shock,  congeni-
tal  malformations,  and  central  nervous  system  depression.
The  corticosteroid  of  choice  is  dexamethasone  and  treat-
ment  is  initiated  at  a  dose  of  0.20  mg/kg/day,  divided  into
two  daily  doses,  which  are  reduced  every  three  days  to
0.15  mg/kg/day  and  ﬁnally,  0.10  mg/kg/day.  The  treatment
is  discontinued  if  the  patient  does  not  show  any  clinical
improvement  up  to  the  3rd  day  of  use.
The  fact  is  that,  in  the  absence  of  alternatives,  in  some
manner  corticosteroids  will  continue  to  be  used  in  the  peri-
natal  period.  It  is  important  to  understand  that,  when  using
corticosteroids  for  the  treatment  of  BPD,  physicians  should
not  be  deluded  by  the  immediate  beneﬁts  only.  And  after
selecting  the  group  that  ﬁts  in  the  treatment,  the  risks  of
adverse  effects  of  corticosteroid  use  in  the  long  term  should
not  be  forgotten,  especially  those  related  to  neurodevel-
opment.  While  the  results  of  studies  and  new  treatment
1127
roposals  are  awaited,  prematurity  prevention,  risk  factor
dentiﬁcation,  and  the  judicious  use  of  corticosteroids  in
peciﬁc  populations  are  the  only  tools  available.
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